MX2021007556A - Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. - Google Patents

Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.

Info

Publication number
MX2021007556A
MX2021007556A MX2021007556A MX2021007556A MX2021007556A MX 2021007556 A MX2021007556 A MX 2021007556A MX 2021007556 A MX2021007556 A MX 2021007556A MX 2021007556 A MX2021007556 A MX 2021007556A MX 2021007556 A MX2021007556 A MX 2021007556A
Authority
MX
Mexico
Prior art keywords
characterization
prediction
cells
systems
hla class
Prior art date
Application number
MX2021007556A
Other languages
English (en)
Inventor
Michael Steven Rooney
Jennifer Grace Abelin
Dominik Barthelme
Robert Kamen
Original Assignee
Biontech Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc filed Critical Biontech Us Inc
Publication of MX2021007556A publication Critical patent/MX2021007556A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation

Abstract

La presente divulgación proporciona un método para preparar una vacuna contra el cáncer personalizada. La presente divulgación también proporciona un método para entrenar un modelo de predicción de presentación de HLA-péptidos de aprendizaje automático.
MX2021007556A 2018-12-21 2019-12-20 Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. MX2021007556A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862783914P 2018-12-21 2018-12-21
US201962826827P 2019-03-29 2019-03-29
US201962855379P 2019-05-31 2019-05-31
US201962891101P 2019-08-23 2019-08-23
PCT/US2019/068084 WO2020132586A1 (en) 2018-12-21 2019-12-20 Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells

Publications (1)

Publication Number Publication Date
MX2021007556A true MX2021007556A (es) 2021-09-10

Family

ID=71101917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007556A MX2021007556A (es) 2018-12-21 2019-12-20 Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.

Country Status (11)

Country Link
US (2) US11183272B2 (es)
EP (1) EP3899954A4 (es)
JP (2) JP7236543B2 (es)
KR (1) KR20210130705A (es)
CN (1) CN113474840A (es)
AU (1) AU2019404547A1 (es)
CA (1) CA3124457A1 (es)
IL (1) IL284195A (es)
MX (1) MX2021007556A (es)
SG (1) SG11202106678PA (es)
WO (1) WO2020132586A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965475T3 (es) * 2017-02-12 2024-04-15 Biontech Us Inc Métodos y composiciones basados en HLA y usos de los mismos
US11176429B2 (en) * 2019-05-13 2021-11-16 International Business Machines Corporation Counter rare training date for artificial intelligence
CA3142227A1 (en) 2019-05-31 2020-12-03 Rubryc Therapeutics, Inc. Meso-scale engineered peptides and methods of selecting
WO2021247858A1 (en) * 2020-06-03 2021-12-09 Xenotherapeutics, Inc. Selection and monitoring methods for xenotransplantation
EP4168569A1 (en) * 2020-06-18 2023-04-26 Personalis, Inc. Machine-learning techniques for predicting surface-presenting peptides
WO2022043881A1 (en) * 2020-08-28 2022-03-03 Immunitybio, Inc. Computerized tool for prediction of proteasomal cleavage
US11403316B2 (en) 2020-11-23 2022-08-02 Peptilogics, Inc. Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates
WO2022119863A1 (en) * 2020-12-01 2022-06-09 Rubryc Therapeutics, Inc. Generalized scaffolds for polypeptide display and uses thereof
CN116583903A (zh) * 2020-12-09 2023-08-11 上海瑞宏迪医药有限公司 基于机器学习的肽免疫原性预测、鉴别系统及方法
KR20230161977A (ko) * 2021-03-25 2023-11-28 제넨테크, 인크. 신경망을 사용한 펩티드 면역원성 예측
CN113807468B (zh) * 2021-10-15 2022-05-27 南京澄实生物科技有限公司 基于多模态深度编码的hla抗原呈递预测方法和系统
WO2023164425A1 (en) * 2022-02-22 2023-08-31 The Children's Hospital Of Philadelphia Systems and methods for generating chimeric major histocompatibility complex (mhc) molecules with desired peptide-binding specificities
WO2024015892A1 (en) * 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
CN114913939B (zh) * 2022-07-19 2022-11-15 北京科技大学 高通量平台和机器学习优化的药物组合设计方法及装置
CN115331728B (zh) * 2022-08-12 2023-06-30 杭州力文所生物科技有限公司 一种稳定折叠的富含二硫键的多肽设计方法及其电子设备
WO2024036308A1 (en) * 2022-08-12 2024-02-15 Biontech Us Inc. Methods and systems for prediction of hla epitopes
CN115333735B (zh) * 2022-10-11 2023-03-14 浙江御安信息技术有限公司 一种数据的安全传输方法
CN116469457B (zh) * 2023-06-14 2023-10-13 普瑞基准科技（北京）有限公司 Mhc与抗原多肽结合、呈递及免疫原性的预测模型训练方法和装置

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
JP3029135B2 (ja) 1991-04-23 2000-04-04 キヤノン株式会社 文字処理装置及び方法
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
WO1995004069A1 (en) 1993-07-30 1995-02-09 Affymax Technologies N.V. Biotinylation of proteins
CA2168950A1 (en) 1993-08-06 1995-02-16 Esteban Celis Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
AU720201B2 (en) 1995-03-08 2000-05-25 Scripps Research Institute, The Antigen presenting system and methods for activation of T-cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
BR9708028A (pt) 1996-03-13 1999-08-03 Analogic Corp Filtro de supressão de anéis auto-calibrador para tomografia computadorizada
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
AU725143B2 (en) 1996-10-17 2000-10-05 Oxford Biomedica (Uk) Limited Retroviral vectors
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
WO1998033891A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
AU745049B2 (en) 1997-03-11 2002-03-07 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
EP1015619A1 (en) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
EP1180159B1 (en) 1999-05-28 2008-09-03 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
JP2004503213A (ja) 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
GB0024550D0 (es) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
WO2002047574A1 (en) 2000-12-15 2002-06-20 Balwinder Singh Aulakh An in vivo method for producing female offsprings in mammals
GB0202334D0 (en) 2001-04-05 2002-03-20 Nextgen Sciences Ltd Protein analysis
CA2457652C (en) 2001-08-31 2012-08-07 Avidex Limited Soluble t cell receptor
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
RU2006134701A (ru) * 2004-03-01 2008-04-10 Пептиммьюн Способы и композиции для лечения аутоиммунных заболеваний
CA2558738C (en) 2004-03-11 2013-02-05 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
NZ550810A (en) 2004-05-19 2009-05-31 Immunocore Ltd High affinity NY-ESO T cell receptor
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
FR2881746B1 (fr) * 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
CA2597928A1 (en) 2005-02-16 2006-08-24 Lentigen Corporation Lentiviral vectors and their use
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
WO2011091319A2 (en) 2010-01-22 2011-07-28 Baylor Research Institute Dendritic cell vaccines
DK2575894T3 (en) 2010-05-28 2015-05-26 Oxford Biomedica Ltd FEED lentiviral vectors FOR BRAIN
NZ612512A (en) 2010-12-09 2015-03-27 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8999937B2 (en) 2011-02-28 2015-04-07 Indiana University Research And Technology Corporation Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2012156969A1 (en) 2011-05-17 2012-11-22 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
NZ730355A (en) * 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
WO2013039889A1 (en) 2011-09-15 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
BR112014027374B1 (pt) 2012-05-03 2022-05-31 Fred Hutchinson Cancer Research Center Método para gerar um receptor de células t (tcr) com afinidade aumentada
SG11201500423TA (en) 2012-07-27 2015-02-27 Univ Illinois Engineering t-cell receptors
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN113699114A (zh) 2013-02-26 2021-11-26 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
JP7114477B2 (ja) * 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
US20190346442A1 (en) * 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
ES2965475T3 (es) * 2017-02-12 2024-04-15 Biontech Us Inc Métodos y composiciones basados en HLA y usos de los mismos
EP3600340A4 (en) * 2017-03-31 2021-01-20 ACT Genomics (IP) Co., Ltd. CLASSIFICATION SYSTEM FOR CANCER-SPECIFIC IMMUNOGENIC EPITOPES
US20210213058A1 (en) * 2018-03-12 2021-07-15 The Children's Hospital Of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy

Also Published As

Publication number Publication date
KR20210130705A (ko) 2021-11-01
US11183272B2 (en) 2021-11-23
JP7236543B2 (ja) 2023-03-09
IL284195A (en) 2021-08-31
SG11202106678PA (en) 2021-07-29
US20220199198A1 (en) 2022-06-23
JP2023071806A (ja) 2023-05-23
EP3899954A4 (en) 2022-09-14
JP2022518355A (ja) 2022-03-15
WO2020132586A1 (en) 2020-06-25
AU2019404547A1 (en) 2021-07-22
EP3899954A1 (en) 2021-10-27
CA3124457A1 (en) 2020-06-25
US20200279616A1 (en) 2020-09-03
CN113474840A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
MX2021007556A (es) Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
PH12016502518A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
GB2570593A (en) Methods relating to intestinal organ-on-a-chip
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
PH12020551436A1 (en) Intracellular delivery of biomolecules to modify immune response
BR112018006350A2 (pt) anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo
MX2018005618A (es) Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
TWD180280S (zh) 電池箱
TWD184928S (zh) 面罩墊之部分
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
EP4218810A3 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
MX2018002849A (es) Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.
MX2018014764A (es) Metodo para producir acido 3-hidroxiadipico.
MX2017000374A (es) Metodos y composiciones que regulan el crecimiento del pelo.
TWD196337S (zh) 口腔保健器具（一）
MX2021002702A (es) Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas.
WO2018075598A8 (en) SYNTHESIS OF EZH2 INHIBITORS
MY183051A (en) Composition containing material for regulating expression of abh antigens
AU2015242879A8 (en) Melatonin secretion regulator, and method for regulating melatonin secretion
TWD192601S (zh) Emulsion tank
Cocco Executive Appointment 55-001; Appointment of Chief of Staff
PH12018502675A1 (en) Methods of priming a sus' immune system
TWD192054S (zh) 吸乳器的配接器